China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
One Percent Rule Checklist For Safer Forex Trading Risk 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
The enormous rally in Kodak shares is expected to continue after its 318 percent increase on Wednesday on the strength of the Trump administration's announcement that will be transformed into a pharmaceutical producer and would receive a $765 million loan to launch Kodak Pharmaceuticals.
The news propelled the company's shares to a more than 200 percent jump in Tuesday trading that continued on Wednesday with the shares ending with a 318 percent increase.
The stocks climbed over 650 percent at its highest on Wednesday, prompting the New York Stock Exchange to halt trading 20 times.
Kodak, a pre-digital era giant producer of film and cameras, filed for bankruptcy in 2012 and pivoted to turn itself into a materials and chemical company.
It emerged as a restructured business in 2013.
Kodak Pharmaceuticals will produce generic active pharmaceutical ingredients to reduce America's dependency on foreign drug makers.
Kodak CEO Jim Continenza noted that since the company already manufactures essential materials for some pharmaceuticals, the new mission is only expanding that capacity.
He added that it would take around three to three and a half years to establish the new production capacity.
